Skip to content

Aurinia 制药

US · AUPH #2749 按市值排名 上市于 1970
16.51 -0.22 -1.32%
实时 - 追踪5344个代码 - 心跳于512秒前 · 2026-10-16 19:31

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了3家。
  • 机构持股总比例下降了2.4个百分点。

机构持股

机构持股比例
64.96% -2.45pp
机构数量
334 -3
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund42.27%
Hedge Fund9.27%
VC/PE Fund6.73%
Public Company4.58%
Individual/Insider2.19%
Government Pension Fund0.77%
Private Company0.71%
Insurance Company0.38%
Family Office/Trust0.15%
Other32.95%

主要股东 截至 2026-06-30

Tang Capital Management, LLC 9.80% · 13.04M 股
BlackRock 6.16% · 8.19M 股
ILJIN SNT Co., Ltd 3.75% · 4.99M 股
Goldman Sachs Asset Management, L.P. 3.67% · 4.88M 股
New Enterprise Associates, Inc. 2.98% · 3.97M 股
Two Sigma Investments, LP 2.61% · 3.47M 股
Arrowstreet Capital, Limited Partnership 2.45% · 3.26M 股
State Street Global Advisors 1.95% · 2.59M 股
Morgan Stanley 1.55% · 2.06M 股
Marshall Wace LLP 1.54% · 2.04M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 27次买入 · 23次卖出

姓名职务持股比例
Peter Greenleaf Chief Executive Officer 0.79%
Matthew Donley Executive Vice President of Operations & Strategy 0.33%
Joseph Miller Chief Financial Officer 0.26%
Stephen Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer 0.23%
David R. Jayne Independent Non-Executive Director 0.03%
Gregory Keenan Chief Medical Officer 0.02%
Jeffrey Bailey Director 0.02%
Craig Johnson Director 0.01%
Jill Leversage Independent Director 0.01%
Karen Smith Director 0.01%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-09 Stephen Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Open Market Disposition -11,939 $15.95
2026-08-20 Stephen Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Open Market Disposition -20,975 $16.97
2026-06-04 Gregory Keenan Chief Medical Officer Intent to Sell (Form 144) -9,593 $16.52
2026-06-03 Tina Nova Independent Director Other Derivative Acquisition +23,931 $15.67
2026-06-03 Craig Johnson Director Other Derivative Acquisition +23,931 $15.67
2026-06-03 Jeffrey Bailey Director Other Derivative Acquisition +23,931 $15.67
2026-06-03 Gregory Keenan Chief Medical Officer Intent to Sell (Form 144) -25,000 $16.34
2026-06-03 Kathleen Goetz -- Other Derivative Acquisition +23,931 $15.67
2026-06-01 Tang Capital Management, LLC -- Open Market Acquisition +814,606 $15.28–15.35
2026-06-01 Tang Capital Management, LLC -- Other Derivative Acquisition +10,000 $15.00
2026-06-01 Gregory Keenan Chief Medical Officer Intent to Sell (Form 144) -25,000 $2,164.00
2026-05-17 Michael Hearne Chief Financial Officer Other Acquisition +116,144 --
2026-05-17 Michael Hearne Chief Financial Officer Other Derivative Acquisition +70,230 $15.28
2026-05-17 Ryan Cole Chief Operating Officer Other Acquisition +116,144 --
2026-05-17 Ryan Cole Chief Operating Officer Other Derivative Acquisition +70,230 $15.28
2026-05-17 Stephen Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Other Acquisition +115,541 --
2026-05-10 Peter Greenleaf Chief Executive Officer Intent to Sell (Form 144) -3,136,201 $15.84
2026-05-10 Joseph Miller Chief Financial Officer Intent to Sell (Form 144) -500,503 $15.84
2026-03-05 Gregory Keenan Chief Medical Officer Sale to Issuer -8,069 $14.32
2026-03-02 Tang Capital Management, LLC -- Open Market Acquisition +898,400 $13.90–14.33

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:31:15 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Aurinia 制药 讨论区 0 条评论

发表评论